{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:25:45Z","timestamp":1785896745481,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3K0641"],"award-info":[{"award-number":["CMRPG3K0641"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3K1401"],"award-info":[{"award-number":["CMRPG3K1401"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CPRPG3E0013"],"award-info":[{"award-number":["CPRPG3E0013"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12072-021-10283-7","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T13:02:47Z","timestamp":1641301367000},"page":"148-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial"],"prefix":"10.1007","volume":"16","author":[{"given":"Wei-Ting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Jung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Heng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ling","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7376-275X","authenticated-orcid":false,"given":"Chau-Ting","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"10283_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941\u20131953","journal-title":"Int J Cancer"},{"key":"10283_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529\u2013538","journal-title":"J Hepatol"},{"key":"10283_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.32723","volume":"147","author":"JL Petrick","year":"2020","unstructured":"Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978\u20132012. Int J Cancer. 2020;147:317\u2013330","journal-title":"Int J Cancer"},{"key":"10283_CR4","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1440-1746.2011.06812.x","volume":"26","author":"YK Cho","year":"2011","unstructured":"Cho YK, Rhim H, Noh S. Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol. 2011;26:1354\u20131360","journal-title":"J Gastroenterol Hepatol"},{"key":"10283_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/00000658-200203000-00009","volume":"235","author":"RT Poon","year":"2002","unstructured":"Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373\u2013382","journal-title":"Ann Surg"},{"key":"10283_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693\u2013699","journal-title":"N Engl J Med"},{"key":"10283_CR7","unstructured":"European associ association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182\u2013236."},{"key":"10283_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u2013380","journal-title":"Hepatology"},{"key":"10283_CR9","doi-asserted-by":"crossref","unstructured":"Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020\u20132.","DOI":"10.1002\/hep.24199"},{"key":"10283_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317\u2013370","journal-title":"Hepatol Int"},{"key":"10283_CR11","doi-asserted-by":"crossref","unstructured":"Kudo M, Trevisani F, Abou-A lfa GK, Rimassa L. Hepatocellular carcinoma: therapeutic guidelines and medical treatment. Liver Cancer 2017;6:16\u201326.","DOI":"10.1159\/000449343"},{"key":"10283_CR12","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1200\/JCO.2011.37.9651","volume":"30","author":"GK Abou-Alfa","year":"2011","unstructured":"Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol. 2011;30:3949\u20133951","journal-title":"J Clin Oncol"},{"key":"10283_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1477-2574.2012.00529.x","volume":"15","author":"JC Henry","year":"2013","unstructured":"Henry JC, Malhotra L, Khabiri H, Guy G, Michaels A, Hanje J, et al. Best radiological response to TACE for hepatocellular carcinoma does not imply better outcomes. HPB. 2013;15:196\u2013202","journal-title":"HPB"},{"key":"10283_CR14","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jhep.2015.01.022","volume":"62","author":"BK Kim","year":"2015","unstructured":"Kim BK, Kim SU, Kim KA, Chung YE, Kim MJ, Park MS, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62:1304\u20131310","journal-title":"J Hepatol"},{"key":"10283_CR15","doi-asserted-by":"crossref","unstructured":"Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, et al. Combination therapy of sorafenib and TACE for unresectable HCC: A systemic review and meta-analysis. PLoS One 2014; 9:e91124.","DOI":"10.1371\/journal.pone.0091124"},{"key":"10283_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 2016;64:1090\u20131098","journal-title":"J Hepatol"},{"key":"10283_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4254\/wjh.v5.i7.364","volume":"5","author":"A Muhammad","year":"2013","unstructured":"Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, et al. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol. 2013;5:364\u2013371","journal-title":"World J Hepatol"},{"key":"10283_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","volume":"47","author":"M Kudo","year":"2011","unstructured":"Kudo M, Imanka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III study of sorafenib after TACE in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117\u20132127","journal-title":"Eur J Cancer"},{"key":"10283_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1634\/theoncologist.2011-0313","volume":"17","author":"D Sansonno","year":"2012","unstructured":"Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359\u2013366","journal-title":"Oncologist"},{"key":"10283_CR20","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69:1492\u20131501","journal-title":"Gut"},{"key":"10283_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejca.2008.10.027","volume":"45","author":"J Bogaerts","year":"2009","unstructured":"Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 2009;45:248\u2013260","journal-title":"Eur J Cancer"},{"key":"10283_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1053\/j.seminoncol.2012.05.004","volume":"39","author":"R Lencioni","year":"2012","unstructured":"Lencioni R. Chemoembolization for hepaocellular carcinoma. Semin Oncol. 2012;39:503\u2013509","journal-title":"Semin Oncol"},{"key":"10283_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360","journal-title":"Semin Liver Dis"},{"key":"10283_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000475777","volume":"6","author":"T Arizumi","year":"2017","unstructured":"Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, et al. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. Liver Cancer. 2017;6:227\u2013235","journal-title":"Liver Cancer"},{"key":"10283_CR25","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1872-034X.2010.00674.x","volume":"40","author":"M Kudo","year":"2010","unstructured":"Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, et al. Response evaluation criteria in cancer of the liver (RECICL) proposed by the liver cancer study group of Japan (2009 revised version). Hepatol Res. 2010;40:686\u2013692","journal-title":"Hepatol Res"},{"key":"10283_CR26","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3390\/ijms21041491","volume":"21","author":"WR Lin","year":"2020","unstructured":"Lin WR, Yeh CT. GALNT14: An emerging marker capable of predicting therapeutic outcomes in multiple cancers. Int J Mol Sci. 2020;21:1491","journal-title":"Int J Mol Sci"},{"key":"10283_CR27","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3892\/ol.2014.2507","volume":"8","author":"KH Liang","year":"2014","unstructured":"Liang KH, Yang PC, Yeh CT. Genotyping the GALNT14 gene by joint analysis of two linked single nucleotide polymorphisms using liver tissues for clinical and geographical comparisons. Oncol Lett. 2014;8:2215\u20132220","journal-title":"Oncol Lett"},{"key":"10283_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2217\/pgs.11.43","volume":"12","author":"KH Liang","year":"2011","unstructured":"Liang KH, Lin CC, Yeh CT. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxanrone and cisplatin in advanced HCC. Pharmacogenomics. 2011;12:1061\u20131073","journal-title":"Pharmacogenomics"},{"key":"10283_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2217\/pgs.15.179","volume":"17","author":"KH Liang","year":"2016","unstructured":"Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, Chang ML, et al. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Pharmacogenomics. 2016;17:353\u2013366","journal-title":"Pharmacogenomics"},{"key":"10283_CR30","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/ijc.28439","volume":"134","author":"CT Yeh","year":"2014","unstructured":"Yeh CT, Liang KH, Lin CC, Chang ML, Hsu CL, Hung CF. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. Int J Cancer. 2014;134:1214\u20131224","journal-title":"Int J Cancer"},{"key":"10283_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41397-019-0106-0","volume":"20","author":"CC Lin","year":"2020","unstructured":"Lin CC, Hsu CW, Chen YC, Chang ML, Liang KH, Lai MW, et al. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics J. 2020;20:57\u201368","journal-title":"Pharmacogenomics J"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10283-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10283-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10283-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T08:52:07Z","timestamp":1700038327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10283-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10283"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10283-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"11 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wei-Ting Chen, Shi-Ming Lin, Wei-Chen Lee, Ting-Jung Wu, Chen-Chun Lin, Chien-Heng Shen, Ming-Ling Chang, Chih-Lang Lin and Chau-Ting Yeh authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study had been approved by Institutional Review Board, Chang Gung Medical Foundation, Taiwan (approval number 104-1686A3). All procedures performed were in accordance with the ethical standards of the responsible committee on human experiments and with the Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients included in this study. This study was registered as ClinicalTrials.gov NCT02504983.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have read and approved the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The de-linked data will be available on request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}]}}